Effects of monoamine oxidase inhibitors on cocaine discrimination in rats

Behavioural Pharmacology

Volumn 17, Issue 2, 2006, Pages 151-159

  Gatch, Michael B ^a   Taylor, Cynthia M ^a   Flores, Elva ^a   Selvig, Meghan ^a   Forster, Michael J ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Cocaine; Dopamine receptors; Drug discrimination; Monoamine oxidase inhibitors; Rat

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; COCAINE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PHENELZINE; SELEGILINE; SODIUM CHLORIDE; TRANYLCYPROMINE;

ANIMAL EXPERIMENT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DISCRIMINATION LEARNING; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SUBSTITUTION; LETHALITY; MALE; METHODOLOGY; MODULATION; NONHUMAN; RAT; RAT STRAIN; TREMOR;

ANIMALS; COCAINE; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; DISCRIMINATION (PSYCHOLOGY); DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33644585183     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fbp.0000197459.08892.b5     Document Type: Article

References (36)

1. Baldessarini RJ (1996). Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. The pharmacological basis of therapeutics, 9th ed, New York: McGraw-Hill. pp. 431-459.
2. Bartzokis G, Beckson M, Newton T, Mandelkern M, Mintz J, Foster JA, et al. (1999). Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 20:582-590.
3. Bergman J, Yasar S, Winger G (2001). Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology 159:21-30.
4. Colpaert FC, Niemegeers CJE, Janssen PAJ (1979). Discriminative stimulus properties of cocaine: neuropharmacological characteristics as derived from stimulus generalization experiments. Pharmacol Biochem Behav 10:535-546.
5. Colpaert FC, Niemegeers CJE, Janssen PAJ (1980). Evidence that a preferred substrate for type B monoamine oxidase mediates stimulus properties of mao inhibitors: a possible role for beta-phenylethylamine in the cocaine cue. Pharmacol Biochem Behav 13:513-517.
6. DeMaster EG, Shirota FN, Nagasawa HT (1986). Role of propiolaldehyde and other metabolites in the pargyline inhibition of rat liver aldehyde dehydrogenase. Biochem Pharmacol 35:1481-1489.
7. Dourish CT, Cooper SJ (1984). Environmental experience produces qualitative changes in the stimulant effects of beta-phenylethylamine in rats. Psychopharmacology 84:132-135.
8. Edwards DJ, Pak KY (1979). Selective radiochemical labeling of types A and B active sites of rat liver MAO. Biochem Biophys Res Commun 86:350-357.
9. Finberg JP, Lamensdorf I, Armoni T (2000). Modification of dopamine release by selective inhibitors of MAO-B. Neurobiology 8:137-142.
10. Gerlach M, Riederer P, Youdim MB (1992). The molecular pharmacology of L-deprenyl. Eur J Pharmacol 226:97-108.
11. Heinonen EH, Anttila MI, Lammintausta RA (1994). Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742-749.
12. Ho BT, McKenna ML (1978). Discriminative stimulus properties of central stimulants. In: Chute DL, editor. Drug discrimination and state dependent learning. New York: Academic Press, pp. 67-77.
13. Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE (2004). Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology 172:31-40.
14. Institute of Laboratory Animal Resources (1996). Guide for the care and use of laboratory animals. Washington, DC: National Academy Press.
15. Johanson C-E, Barrett JE (1993). The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther 267:1-8.
16. Koob GF, Nestler EJ (1997). The neurobiology of drug addiction [review] [169 refs]. J Neuropsychiatry Clin Neurosci 9:482-497.
17. Lajtha A, Sershen H, Cooper T, Hashim A, Gaal J (1996). Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration. Neurochem Res 21:1155-1160.
18. Lamensdorf I, Porat S, Simantov R, Finberg JP (1999). Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol 126:997-1002.
19. Martin KF, Phillips I, Cheetham SC, Heal DJ (1995). Dopamine D2 receptors: a potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments. Pharmacol Biochem Behav 51:565-569.
20. McKenna KF, Baker GB, Courts RT, Rauw G, Mozayani A, Danielson TJ (1990). Recent studies on the MAO inhibitor phenelzine and its possible metabolites. J Neural Transm Suppl 32:113-118.
21. Mercuri NB, Scarponi M, Bonci A, Siniscalchi A, Bernardi G (1997). Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 17:2267-2272.
22. Neff NH, Yang HY (1974). Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci 14:2061-2074.
23. Parent MB, Habib MK, Baker GB (2000). Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine. Biochem Pharmacol 59:1253-1263.
24. Peltier RL, Li D-H, Lytle DA, Taylor CM, Emmett-Oglesby MW (1996). Chronic D-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine. J Pharmacol Exp Ther 277:212-218.
25. Perez V, Pasto M, Unzeta M (2000). Involvement of Ca2+ in dopamine release in striatal rat slices by PF9601N and L-deprenyl. Neurobiology 8:237-242.
26. Porsolt RD, Pawalec C, Roux S, Jalfre M (1984). Discrimination of the amphetamine cue: effects of A, B and mixed type inhibitors of monoamine oxidase. Neuropharmacology 23:569-573.
27. Resnick RB (2003). Food and Drug Administration approval of buprenorphinenaloxone for office treatment of addiction. Ann Intern Med 138:36.
28. Robinson SE (2002). Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 8:377-390.
29. Salach JI, Detmer K, Youdim MB (1979). The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl. Mol Pharmacol 16:237-241.
30. Sherry RL, Rauw G, McKenna KF, Paetsch PR, Courts RT, Baker GB (2000). Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine. J Affect Disord 61:23-29.
31. Standaert DG, Young AB (1996.) Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill. pp. 503-519.
32. Timar J (1989). Recovery of MAO-B enzyme activity after (-)deprenyl (selegiline) pretreatment, measured in vivo. Acta Physiol Hung 74:259-266.
33. Turkish S, Yu PH, Greenshaw AJ (1988). Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects. J Neural Transm 74:141-148.
34. Woolverton WL (1990). A review of the pharmacology of the discriminative stimulus effects of cocaine. Psychopharmacology 101:S76.
35. Yasar S, Schindler CW, Thorndike EB, Szelenyi I, Goldberg SR (1993). Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J Pharmacol Exp Ther 256:1-6.
36. Yasar S, Schindler CW, Thorndike EB, Goldberg SR (1994). Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats. Eur J Pharmacol 259:243-250.